Man­u­fac­tur­ing com­pa­ny Re­silience hit sev­er­al high points in 2022 in se­cur­ing an­oth­er fund­ing round and net­ting part­ner­ships with ma­jor play­ers, and now it’s start­ing the new year with a deal that moves it out­side North Amer­i­ca for the first time.

On Tues­day, Re­silience an­nounced that the Abu Dhabi-based sov­er­eign in­vestors, the Mubadala In­vest­ment Com­pa­ny, inked an eq­ui­ty in­vest­ment. The two par­ties will col­lab­o­rate on a bio­phar­ma man­u­fac­tur­ing plan to build a new man­u­fac­tur­ing fa­cil­i­ty in Abu Dhabi. As per the deal, Mubadala will es­tab­lish the fa­cil­i­ty and Re­silience will op­er­ate it. The Abu Dhabi fa­cil­i­ty will man­u­fac­ture a range of prod­ucts, in­clud­ing ther­a­pies for can­cer and in­fec­tious dis­eases, along with vac­cines and oth­er prod­ucts.

Re­silience will pro­vide the man­u­fac­tur­ing along with the tech­nol­o­gy and “ex­per­tise,” and in­cor­po­rate it in­to its glob­al net­work and giv­ing the com­pa­ny a foothold in the Mid­dle East. The ex­act de­tails of where the fa­cil­i­ty will be lo­cat­ed, along with the size and time­line for com­ple­tion, were not dis­closed.

“This will be Re­silience’s first man­u­fac­tur­ing fa­cil­i­ty out­side of North Amer­i­ca, a sig­nif­i­cant mile­stone for the com­pa­ny, rep­re­sent­ing that Re­silience is seen as a trust­ed part­ner who will bring ad­vanced bio­man­u­fac­tur­ing tech­nolo­gies and op­er­at­ing sys­tems to the re­gion. This will al­low the re­gion to be­come self-suf­fi­cient and re­silient to changes,” said Re­silience CEO Rahul Singhvi, in an emailed state­ment to End­points News.

The specifics of the fi­nan­cial in­vest­ment were al­so not dis­closed, but Singhvi said Mubadala had in­vest­ed in mul­ti­ple rounds of eq­ui­ty fi­nanc­ing at Re­silience and that this Mubadala in­vest­ment is in­clud­ed in the “ag­gre­gate round sizes” that have been pre­vi­ous­ly an­nounced. Singhvi al­so not­ed that some of the board mem­bers of Re­silience have a pri­or re­la­tion­ship with Mubadala. Re­silience raised $625 mil­lion in a Se­ries D in June of last year.

“Through this agree­ment, Mubadala and its group com­pa­nies will un­lock fur­ther op­por­tu­ni­ties for growth with­in the life sci­ences ecosys­tem, and along­side our key part­ners, will play an in­stru­men­tal role in es­tab­lish­ing a state-of-the-art bio­phar­ma cam­pus that will se­cure the re­gion’s sup­ply chain from Abu Dhabi,” said Badr Al-Ola­ma the ex­ec­u­tive di­rec­tor of UAE Clus­ters at Mubadala, in a state­ment.

Abu Dhabi has been work­ing to boost phar­ma man­u­fac­tur­ing in the coun­try. In late De­cem­ber, As­traZeneca and Abu Dhabi-based G42 Health­care inked a strate­gic man­u­fac­tur­ing deal to make drugs in Abu Dhabi. That man­u­fac­tur­ing deal will fo­cus on R&D and “lo­cal­iz­ing” in­dus­tries to pro­duce phar­ma prod­ucts, as As­traZeneca al­so has “on­go­ing ef­forts” with the De­part­ment of Health of Abu Dhabi. Abu Dhabi al­so has un­veiled plans to dou­ble the size of its man­u­fac­tur­ing sec­tor by 2031.

Re­silience spent last year ce­ment­ing its pres­ence in North Amer­i­ca. In No­vem­ber, it pur­chased an As­traZeneca man­u­fac­tur­ing fa­cil­i­ty in West Chester, OH, just north of Cincin­nati. Re­silience will pro­duce “se­lect” As­traZeneca med­i­cines at the fa­cil­i­ty as part of the sup­ply agree­ment.

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Over the past several years, Massachusetts-based contractor Charles River Laboratories has been busy on the M&A front, with the latest, $50 million buyout coming Monday for a provider of high-throughput screening solutions for discovery research.

Chicago-based SAMDI Tech will now be folded into Charles River’s discovery and safety assessment division, Charles River announced.

The $50 million in cash is for the 80% of SAMDI that Charles River didn’t previously own. Other financial details on the deal were not disclosed.

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.